drugset / Trial / NCT02779569
A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)
RandomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the safety and clinical efficacy of ultra-low-dose decitabine in Chinese MDS
Timeline
- Start
- 2016-03
- Primary completion
- 2019-03
- Completion
- 2019-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 5 mg/m2 | Subcutaneous |
| Subject | Decitabine | Small molecule | 7 mg/m2 | Subcutaneous |
| Subject | Decitabine | Small molecule | 20 mg/m2 | Subcutaneous |